Pharvaris Shares Soar 79% on Hereditary Angioedema Treatment PHVS416 Data

By Denny Jacob

Pharvaris NV shares soared 79%, to $4.50, in early trading after the company said data on PHVS416 demonstrated statistically significant results for treatment of hereditary angioedema, a hereditary condition that causes recurrent swelling.

Top-line data from the Phase 2 study of PHVS416 for the prophylactic treatment of hereditary angioedema is expected in the second half of 2023, said Chief Executive Berndt Modig. Data from the proof-of-concept study is expected to inform the design of expected Phase 3 utilizing PHVS719, an investigational treatment currently in Phase 1 clinical development for hereditary angioedema.

The clinical-stage biopharmaceutical company also said it is continuing to work with the U.S. Food and Drug Administration to resolve holds on clinical trials for PHA121, which the company describes as a competitive antagonist of the bradykinin B2 receptor.

Write to Denny Jacob at [e-mail]

(END) Dow Jones Newswires

12-08-22 1020ET